Fig. 4From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectivesPercent of patients reaching the primary end point (a) and reduction in glycated hemoglobin level (b) after 24 weeks of intervention in the sotagliflozin group compared to placebo group as reported in inTandem 3 trialBack to article page